Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
2006 Standout
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
1989 Standout
True
2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
2000
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
1995
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients
1989
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
2002
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Association of serum albumin and mortality risk
1997
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non‐small‐cell lung cancer
1996
Cisplatin Binding Sites on Human Albumin
1998
Head and neck cancer
2008 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Pharmacodynamics in cancer therapy.
1990
Fumonisins, mycotoxins of increasing importance: Their nature and their effects
1996
Esophageal Cancer
2003 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin
1987
Global cancer statistics
2011 Standout
Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease
1998 Standout
Diagnostic and therapeutic management of cancer of an unknown primary
2003
A Randomized, Double‐Blind, Double‐Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients
2001
Oesophageal carcinoma
2013 Standout
Echinocandin antifungal drugs
2003 Standout
Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.
1987
Cancer Chemotherapy in Older Adults
1997
Iproplatin and carboplatin induced toxicities: Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG)
1988
Epirubicin
1993
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis
2014 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
1992 Standout
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
2004
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
MicroRNA expression profiles classify human cancers
2005 StandoutNatureNobel
Clinical Pharmacokinetics of Carboplatin
1988
Are claims of equivalency in digestive diseases trials supported by the evidence?☆
2004
Excess Incidence of Squamous Cell Esophageal Cancer among US Black Men: Role of Social Class and Other Risk Factors
2001
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Scope and Impact of Financial Conflicts of Interest in Biomedical Research
2003 Standout
Black (air-cured) and blond (flue-cured) tobacco and cancer risk III: Oesophageal cancer
1993
Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
1999
3d Transition Metals for C–H Activation
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Fumonisin contamination of commercial corn-based human foodstuffs
1991
Carboplatin: the clinical spectrum to date
1985
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
Total synthesis of natural productsviairidium catalysis
2017
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Mycotoxins
2003 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.
1987
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine
1986
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review
2000
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
1987
A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
2006 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Guidelines for Treatment of Candidiasis
2004 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Nephrotoxicity Induced by Cancer Chemotherapy With Special Emphasis on Cisplatin Toxicity
1986
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes
2012 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Informing etiologic research priorities for squamous cell esophageal cancer in Africa: A review of setting‐specific exposures to known and putative risk factors
2016
Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials
2002 Standout
Works of M. Beer being referenced
Fluconazole versus Amphotericin B in the Treatment of Esophageal Candidiasis in Cancer Patients
1996
A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia
1997
Factors influencing complete response and survival in patients with head and neck cancer treated with platinum-based induction chemotherapy
1992
Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site
1992
A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer
1994
Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates
2009
Factors associated with oesophageal cancer in Soweto, South Africa
1988
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a hellenic co-operative oncology group study
1996
High-Dose Epirubicin as a Single Agent in the Treatment of Patients with Advanced Breast Cancer
1991
Phase II study of ortataxel in taxane-resistant breast cancer
2008
A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer
1992
Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer.
1992
Phase I study of carboplatin given on a five-day intravenous schedule.
1983
Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma
1980
[BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study].
1994